498.43
-23.82 (-4.56%)
| Penutupan Terdahulu | 522.25 |
| Buka | 523.04 |
| Jumlah Dagangan | 2,216,132 |
| Purata Dagangan (3B) | 1,465,783 |
| Modal Pasaran | 126,504,239,104 |
| Harga / Pendapatan (P/E TTM) | 30.96 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.78 |
| Harga / Jualan (P/S) | 11.15 |
| Harga / Buku (P/B) | 6.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | -8.91% |
| Margin Operasi (TTM) | 37.22% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
| Nisbah Semasa (MRQ) | 2.65 |
| Aliran Tunai Operasi (OCF TTM) | -980.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
| Pulangan Atas Aset (ROA TTM) | 11.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vertex Pharmaceuticals Incorpor | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 97.64% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BOZIC CARMEN | - | 491.34 | -596 | -292,839 |
| LIU JOY | - | 498.01 | -828 | -412,352 |
| MCKECHNIE DUNCAN | - | 528.04 | -1,541 | -813,710 |
| TATSIS OURANIA | - | 528.04 | -1,500 | -792,060 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,465 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,310,961 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 511.36 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MCKECHNIE DUNCAN | Pegawai | 02 Jul 2026 | Jual automatik (-) | 1,541 | 528.04 | 813,710 |
| TATSIS OURANIA | Pegawai | 02 Jul 2026 | Jual automatik (-) | 1,500 | 528.04 | 792,060 |
| LIU JOY | Pegawai | 01 Jul 2026 | Jual automatik (-) | 828 | 498.01 | 412,352 |
| BOZIC CARMEN | Pegawai | 26 Jun 2026 | Jual automatik (-) | 596 | 491.34 | 292,839 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |